Case Report
Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma

Megan G. Lockyer, D.O., Michael T. Deavers, M.D., and Neda Zarrin-Khameh, M.D., M.P.H.

Summary: A 64-yr-old postmenopausal woman with high-grade squamous intraepithelial lesion and atypical glandular cell of undetermined significance on her Pap test was found to have endometrial serous carcinoma (high grade) involving a polyp in a subsequent endometrial biopsy. She underwent hysterectomy and bilateral salpingo-oophorectomy with multiple biopsies of the peritoneum. Microscopic examination of the entirely submitted uterus showed no residual serous carcinoma. Multiple foci of low-grade serous tumor with extensive calcifications and psammoma bodies were identified on the surfaces of the left fallopian tube, ovaries, and biopsies of the peritoneum, consistent with peritoneal primary low-grade serous carcinoma. To our knowledge, this is the first reported case of low-grade serous carcinoma of the peritoneum with a concurrent (high-grade) serous carcinoma of the endometrium arising from an endometrial polyp. Key Words: Serous carcinoma of endometrium—Low-grade serous carcinoma of peritoneum—Endometrial polyp.

Histogenesis of primary peritoneal serous carcinoma is not clear and the most common theory hypothesizes that it originates from preexisting endosalpingiosis as their common origin is the Mullerian ductal system. Recently the fallopian tube, particularly the fimbrial end, has been proposed as a potential site of origin of some ovarian or peritoneal serous cancers. We encountered a case of low-grade serous carcinoma of the peritoneum with a concurrent (high-grade) serous carcinoma of the endometrium arising from an endometrial polyp. To our knowledge, this association has not been reported and we hope that this incident may shed some light on the etiology of primary peritoneal serous carcinoma.

CASE REPORT
A 64-yr-old G6P5014 postmenopausal woman presented for routine Pap test and well woman examination. Her family history was significant for endometrial cancer in her mother, endometrial cancer in one of her sisters at the age of 52, and liver cancer in her other sister. She had no complaint of vaginal bleeding. Her last menstrual period was in 1997. According to the patient her last Pap tests were reported normal. Her Pap test at this visit was significant for high-grade squamous intraepithelial lesion and atypical glandular cell of undetermined significance. Her subsequent cervical biopsy and endometrial biopsy demonstrated pleomorphic cells with high nuclear to cytoplasmic ratio and hyperchromatic nuclei (Figs. 1, 2). Mitotic figures were seen. By immunohistochemistry, the neoplastic cells were reactive for p16, ER, WT1, p53 (diffuse and strong nuclear staining), and low-molecular cytokeratin.
Vimentin, CEA, and β-catenin were negative. The patient was diagnosed with uterine serous carcinoma and underwent hysterectomy, bilateral salpingo-oophorectomy, and staging.

On gross examination, the uterus was unremarkable except for a 2.2 × 1.4 × 0.9 cm leiomyoma in the posterior wall and an endometrial polyp. Bilateral ovaries and fallopian tubes had no discrete lesions. Anterior and posterior vaginal margins, omentum, left pericolic nodules, and lymph nodes from the pelvis, bilateral common iliacs, bilateral obturators, and para-aortic were also received.

No tumor was identified in the entirely submitted endometrium. There were multiple foci of low-grade peritoneal serous carcinoma with extensive calcifications and psammoma bodies on the surfaces of both of the ovaries and left fallopian tube (Figs. 3–5). The tumor in the pericolic nodules and omentum (Figs. 6–8) had identical cytomorphologic features. The same immunohistochemical stains performed on the endometrial carcinoma were performed on the peritoneal lesion. Peritoneal lesions were focally positive with vimentin. They were strongly and diffusely positive with CAM 5.2, low–molecular-weight cytokeratin, β-catenin, and ER (nuclear). They were negative with CEA.

All of the lymph nodes were negative for malignancy. A final diagnosis of primary peritoneal carcinoma, low grade, was established.
The pelvic washing had sheets of mesothelial cells and psammoma bodies with rare groups of neoplastic cells with high nuclear to cytoplasmic ratio and hyperchromatic nuclei. These cells cytomorphologically were similar to the neoplastic cells of the peritoneal low-grade serous carcinoma. They were positive for ER and focally positive for p53.

After further review of the endometrial biopsy, it was deemed that the neoplastic cells were confined to an endometrial polyp (Figs. 9 and 10). Since the endometrium had been entirely submitted for microscopic evaluation and no invasive carcinoma was identified, we concluded that the serous carcinoma had been limited to the polyp.

Endometrial and peritoneal lesions were evaluated for Kras and BRAF V600E/K/D mutations. Both lesions were negative for these mutations.

FIG. 5. Low-grade peritoneal serous carcinoma. Monomorphic cells associated with psammoma bodies are seen. Hematoxylin and eosin stain, original magnification: × 100.

FIG. 6. The tumor in the omentum with identical cytomorphologic features; monomorphic cells with associated psammoma bodies. Hematoxylin and eosin stain, original magnification: × 40.

FIG. 7. The tumor in the omentum with identical cytomorphologic features; monomorphic cells with associated psammoma bodies. Hematoxylin and eosin stain, original magnification: × 40.

FIG. 8. The tumor in the omentum with identical cytomorphologic features; monomorphic cells with associated psammoma bodies. Hematoxylin and eosin stain, original magnification: × 40.

DISCUSSION

The prevalence of endometrial polyp in the general population is about 24%, although they are more common in postmenopausal woman (1–6). The literature suggests up to 8% risk of malignant transformation of an endometrial polyp, with the risk higher in postmenopausal women, especially if they present with bleeding and have large polyps (7–10). Interestingly, 12% to 34% of uteri containing endometrial carcinoma also contain polyps (11,12).
Many patients with adenocarcinoma in an endometrial polyp (8 of 9, 90% in 1 study) have adenocarcinoma or complex atypical hyperplasia of the nonpolyp endometrium, indicating a need for hysterectomy in most of these cases, particularly if the patient is postmenopausal (13,14). Although our patient had high-grade serous carcinoma in an endometrial polyp, she did not have any malignancy in the rest of endometrium or in the second endometrial polyp.

Although serous carcinoma of endometrium can metastasize extensively, the chance of the peritoneal tumor to be metastatic from the serous carcinoma involving endometrial polyp in our patient is unlikely, as the tumor cells on the serosal surface are low grade, whereas the endometrial carcinoma is high grade. The more typical association of serous carcinoma in a polyp is with high-grade serous carcinoma in the peritoneum (15). Patients with primary peritoneal serous carcinoma have a mean age of 50 to 65yr (16–18). Abdominal pain and ascites are common presenting signs and symptoms (16).

The most commonly accepted criteria for peritoneal primary serous carcinoma are Gynecology Oncology Group criteria; which includes the following (i) the ovaries were either absent or normal in size; (ii) the involvement of the extraovarian sites was greater than the involvement of the surface of either ovary; (iii) an absence of a deep-seated invasive ovarian carcinoma or invasive disease in the ovarian cortical stroma with tumors that were <5 × 5mm²; (iv) the histopathologic and cytologic characteristics of the tumors were similar to that for epithelial ovarian cancer (19).

On the basis of Gynecology Oncology Group criteria, as the ovaries in this patient were of normal size; the involvement of the extraovarian sites was greater than the involvement of the surface of either ovary; absence of a deep-seated invasive ovarian carcinoma and characteristic cytomorphology of the lesions, primary peritoneal serous carcinoma was diagnosed.

Endosalpingiosis in the peritoneum is commonly found concurrently with implants of serous borderline tumors of ovary that has metastasized to the peritoneum (20). This finding has sparked the theory that primary peritoneal serous carcinoma may arise from preexisting endosalpingiosis (21). However, the histogenesis of this tumor remains undetermined. As the surface epithelium of the ovary, the peritoneum, and subjacent connective tissue all originate from coelomic epithelium and subcoelomic mesenchyme, which are derived embryologically from the Mullerian ductal system, it could be maintained that endosalpingiosis, serous borderline tumors, and even peritoneal serous carcinomas are derivatives of the secondary Mullerian system. Indeed, this has been one the most accepted theories, as these tumors are derived from cells that retain a potential for Mullerian differentiation, and could account for the simultaneous occurrence of these entities (20–24).
Recently the fallopian tube, particularly the fimbrial end, has been proposed as a potential site of origin of some ovarian or peritoneal serous cancers (25–27). It has been shown that intraluminal shedding of tumor cells in the fallopian tubes from serous carcinoma cases are common and a likely route of abdominal spread (28). Our patient had psammoma bodies in the endothelial lining of fallopian tube, but no associated epithelial cells or mucosal dysplasia was found.

Although our patient’s uterus and adnexa were grossly normal, she had pericolic nodules described in the operative report as small (2 mm) white punctate lesions that were found to contain serous carcinoma.

The differential diagnosis of primary peritoneal serous carcinoma includes endometriosis, endosalpingiosis, adenomatoid tumor, florid mesothelial hyperplasia, papillary mesothelioma, primary ovarian papillary serous borderline tumor with implants, and primary peritoneal serous papillary carcinoma. Although the other entities can often be distinguished by morphology and architecture alone, immunohistochemistry may be useful in some instances. Calretinin can be used to distinguish mesothelial lesions.

Primary peritoneal serous carcinoma is currently treated similar to primary ovarian serous carcinoma with platinum-based chemotherapy (22). Our patient underwent radiation therapy followed with combination carboplatin/taxol chemotherapy.

We believe this is the first reported case of synchronous primary peritoneal low-grade serous carcinoma and a (high-grade) serous carcinoma of endometrium. Although this may be an incidental finding, it may also indicate a common histogenetic pathway for these tumors. Additional cases and further studies are required for the evaluation of this hypothesis.

REFERENCES

1. Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. *Am J Obstet Gynecol* 1997;177:102–8.

2. Nagele F, O’Connor H, Davies A, et al. 2500 outpatient diagnostic hysteroscopies. *Obstet Gynecol* 1996;88:87–92.

3. Van Bogaert LJ. Clinicopathologic findings in endometrial polyps. *Obstet Gynecol* 1988;71:771–3.

4. Dreisler E, Stampe Sorensen S, IbSEN PH, et al. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. *Ultrasound Obstet Gynecol* 2009;33:102–8.

5. Lieng M, Istrate O, Sandvik L, et al. Prevalence, 1-year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study. *J Minim Invasive Gynecol* 2009;16:465–71.

6. Reslova T, Tosner J, Resl M, et al. Endometrial polyps. A clinical study of 245 cases. *Arch Gynecol Obstet* 1999;262:133–9.

7. Savelli L, De Iaco P, Santini D, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. *Am J Obstet Gynecol* 2003;188:927–31.

8. Costa-Paiva L, Godoy CE, Jr Antunes A, Jr, et al. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. *Menopause* 2011;18:1278–82.

9. Antunes A, Jr Costa-Paiva L, Arthuso M, et al. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy. *Maturitas* 2007;57:415–21.

10. Lee SC, Kaunitz AM, Sanchez-Ramos L, et al. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. *Obstet Gynecol* 2010;116:1197–205.

11. Peterson WF, Novak ER. Endometrial polyps. *Obstet Gynecol* 1956;8:40–9.

12. Salm R. The incidence and significance of early carcinomas in endometrial polyps. *J Pathol* 1972;108:47–53.

13. Rahimi S, Marani C, Renzi C, et al. Endometrial polyps and the risk of atypical hyperplasia on biopsies of unremarkable endometrium: a study on 694 patients with benign endometrial polyps. *Int J Gynecol Pathol* 2009;28:222–8.

14. Mittal K, Da Costa D. Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. *Int J Gynecol Pathol* 2008;27:45–8.

15. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. *Mod Pathol* 1990;3:120–8.

16. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. *Obstet Gynecol* 1990;75:89–95.

17. Rothenberger D, Mobius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. *Int J Gynecol Pathol* 1995;14:310–8.

18. Iavazzo C, Vorgias G, Katsoulis M, et al. Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics. *Arch Gynecol Obstet* 2008;278:53–6.

19. Bliss JD, Brady MF, Liu SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study. *Gynecol Oncol* 2003;89:148–54.

20. Biscotti CV, Hart WR. Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum). A clinicopathologic study of 17 cases. *Am J Surg Pathol* 1992;16:467–75.

21. Fox H. Primary neoplasia of the female peritoneum. *Arch Gynecol Obstet* 1999;267:50–8.

22. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. *Obstet Gynecol* 1990;75:89–95.

23. Hutton RL, Dalton SR. Primary peritoneal serous borderline tumors. *Am J Surg Pathol* 1998;22:171–8.

24. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. *Arch Pathol Lab Med* 2011;135:138–44.

25. Silva EG, Tornos C, Zhang Z, et al. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. *Int J Gynecol Pathol* 1998;17:1–6.

26. Agoff SN, Mendelin JE, Greico VS, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. *Am J Surg Pathol* 2002;26:171–8.

27. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. *Gynecol Oncol* 2002;87:52–6.

28. Levine DA, Argenta PA, Yee C, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222–7.

29. Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. *Am J Surg Pathol* 2013;37:1123–30.